Why Complicated UTIs Are Hard to Treat

More Than a Bladder Infection

Simple bladder infections usually respond to standard oral antibiotics. Complicated UTIs involve the upper urinary tract, occur alongside structural or functional urinary problems, or develop in people with catheters, kidney stones, obstruction, or recent urologic procedures. Pyelonephritis, or kidney infection, falls in this category and can become severe quickly.

Resistance Narrows the Options

Many complicated UTIs are caused by gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Some produce extended-spectrum beta-lactamases, AmpC enzymes, or carbapenemases, which inactivate many antibiotics. When standard options fail, clinicians may need agents that remain active against these organisms, but they must be used carefully to avoid worsening resistance.

Who Is at Higher Risk

Risk factors include urinary catheters, recent hospitalization, prior antibiotic exposure, diabetes, urinary obstruction, pregnancy, and older age. People with weakened immune systems are more vulnerable to serious infection.

Key Takeaways

• Fetroja (cefiderocol) received FDA approval on November 14, 2019, for adults with cUTI, including pyelonephritis, caused by susceptible gram-negative organisms with limited or no alternative options.
• Cefiderocol is a siderophore cephalosporin: it binds iron and uses bacterial iron-transport systems to enter gram-negative cells.
• In APEKS-cUTI, 72.6 percent of cefiderocol recipients met the composite endpoint, and the drug met noninferiority compared with imipenem/cilastatin.
• The label carries a warning about higher all-cause mortality seen in the CREDIBLE-CR trial among critically ill patients with carbapenem-resistant infections. The FDA said the cause was not established.
• A September 2020 approval extended the label to hospital-acquired and ventilator-associated bacterial pneumonia.
• Fetroja is given by IV infusion, requires kidney-based dose adjustment, and is reserved for infections proven or strongly suspected to be caused by susceptible bacteria.

What Is Fetroja

Brand and Generic Names

Fetroja is the brand name for cefiderocol, developed by Shionogi. The drug is supplied as an injection for intravenous use. It is not available as a tablet.

Drug Class

Cefiderocol is a cephalosporin, a member of the beta-lactam family. Its structure includes a catechol group that allows it to bind iron. This is what makes it a siderophore cephalosporin, a category that is new to the U.S. market.

Why It Matters Clinically

Many resistant gram-negative bacteria have evolved to defeat older beta-lactams and carbapenems. Cefiderocol was designed to reach these organisms through a different route, which is why it is kept for serious infections with limited alternatives.

FDA Approval: November 14, 2019

The Decision

The FDA approved Fetroja on November 14, 2019, for adults aged 18 and older with cUTI, including kidney infections, caused by susceptible gram-negative microorganisms who have limited or no alternative treatment options. The FDA's announcement noted that the safety and effectiveness were demonstrated in a study of 448 patients with cUTI.

Advisory Committee Support

The FDA's Antimicrobial Drugs Advisory Committee voted 14 to 2 in favor of approval in October 2019, before the final decision.

Special Designations

Fetroja received the Qualified Infectious Disease Product designation, which brings priority review. The FDA granted priority review so the agency could act within an accelerated timeframe.

The Warning Attached to Approval

The FDA's announcement highlighted that the label includes a warning about higher all-cause mortality observed in cefiderocol-treated patients compared with those receiving other antibiotics in a trial of critically ill patients with multidrug-resistant infections. This warning is central to safe use and is discussed in detail below.

The Siderophore Trick Explained

Why Bacteria Need Iron

Iron is essential for bacterial growth. Many bacteria secrete small molecules called siderophores that capture iron from the environment, then use dedicated transporter proteins to carry the iron back into the cell.

How Cefiderocol Uses It

Cefiderocol mimics that process. Its iron-binding structure lets it be recognized by the bacterial iron-uptake machinery, so the antibiotic is carried through the outer membrane that normally blocks many drugs. Researchers describe this as a Trojan horse strategy.

Why This Helps

Many resistance mechanisms work by keeping antibiotics out or pumping them out. A drug that enters through an iron-transport route can remain effective when entry is the problem. This does not make the drug invincible, but it gives clinicians a different tool.

How Cefiderocol Kills Bacteria

Cell Wall Targeting

Once inside, cefiderocol binds penicillin-binding proteins, disrupting cell wall construction in the same general way other cephalosporins do. The bacterium weakens and dies.

Stability Against Enzymes

Cefiderocol is designed to resist hydrolysis by many beta-lactamases, including several carbapenemases. Stability against these enzymes is a major reason it remains active against organisms that defeat other agents.

Limits

Some organisms, including certain strains with specific enzyme profiles or porin changes, can still be resistant. Susceptibility testing is necessary for each infection.

Which Bacteria It Targets

Labeled Organisms for cUTI

The cUTI label covers susceptible strains of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and other gram-negative organisms named in the current prescribing information. Confirm the full list before relying on it.

Resistant Gram-Negatives

Cefiderocol was studied in populations with carbapenem-resistant organisms, which is why it is considered a last-line option for serious infections. Its activity against multidrug-resistant organisms is an important reason clinicians consider it.

Not a Gram-Positive Drug

Fetroja is designed for gram-negative infections. It is not the treatment for staphylococcal or enterococcal infections.

Approved Uses and Labeling Limits

Who Is Eligible

The approved cUTI population is adults aged 18 and older with susceptible gram-negative infections who have limited or no alternative treatment options.

Stewardship Statement

The label states that Fetroja should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This language is meant to protect the drug's future effectiveness.

Not Approved For

The cUTI approval does not cover uncomplicated UTIs or children. Pneumonia indications were added later, as discussed below. Use outside the labeled indications is a clinical judgment for the treating team.

The APEKS-cUTI Trial

Design

APEKS-cUTI was a randomized, double-blind, multicenter, noninferiority trial comparing cefiderocol with imipenem/cilastatin in adults with cUTI, including pyelonephritis. The trial enrolled 448 patients, and the FDA relied on it as the basis for the cUTI approval.

Comparator

Imipenem/cilastatin is a carbapenem commonly used for serious gram-negative infections. Comparing against it asks whether cefiderocol performs at least as well as an established option.

Primary Endpoint

The primary endpoint was a composite of microbiological eradication and clinical response at the test-of-cure visit. Requiring both bacterial clearance and symptom resolution makes the measure demanding.

Trial Results Explained

Efficacy

In APEKS-cUTI, 72.6 percent of patients receiving cefiderocol met the composite endpoint. The drug met the prespecified noninferiority criterion compared with imipenem/cilastatin. Noninferiority means it was not meaningfully worse than the comparator within a set margin.

Reading the Numbers

A composite endpoint can hide differences between its parts. Patients may achieve clinical response without full microbiological clearance, or the reverse. Clinicians look at both components when interpreting results.

Population Limits

APEKS-cUTI enrolled selected patients who met study criteria. Real-world patients may be older, sicker, or have different organisms, and the results should not be assumed to apply equally to everyone.

The CREDIBLE-CR Trial and Mortality Warning

Design

CREDIBLE-CR was an open-label study that compared cefiderocol with best available therapy in critically ill patients with serious infections caused by carbapenem-resistant gram-negative bacteria. The population included nosocomial pneumonia, bloodstream infections, and sepsis from urinary or other sources.

What Was Observed

The trial found clinical and microbiological efficacy similar to best available therapy, but all-cause mortality was higher in the cefiderocol group. This was the finding that led to the boxed warning.

What the FDA Said

The FDA reviewed the trial and noted that the cause of the mortality imbalance had not been established. Some deaths were related to worsening infection, complications, or underlying illness. The agency also noted limitations in interpreting an open-label trial that was not designed as a fully controlled comparison for all infection types.

Why It Matters for Serious Infections

The concern is most relevant to critically ill patients with carbapenem-resistant bacteremia, sepsis, or hospital-acquired pneumonia. In those settings, the benefit-risk balance is especially delicate.

What the Mortality Warning Means for You

It Is Not a Simple Yes or No

The warning does not mean that cefiderocol kills people. It means that in one trial, more patients died in the cefiderocol group than in the comparison group, and the reason is unclear. The FDA weighed this against the benefit for cUTI and approved the drug for a narrow use.

Why Clinicians Still Use It

For some patients with resistant gram-negative infections and few alternatives, the benefit may outweigh the risk. Infectious disease specialists weigh culture results, severity, and available options before deciding.

Questions Worth Asking

Ask your team whether cefiderocol is the best choice given your infection and alternatives, what monitoring is planned, and how the decision was reached. A good care team welcomes these questions.

Administration and Dosing

IV Infusion

Fetroja is given by intravenous infusion. The FDA labeling describes a 3-hour infusion for the standard regimen, which nurses and pharmacists manage in hospital or infusion settings.

Labeled Regimen

The standard regimen is 2 grams given every 8 hours for cUTI, with changes based on kidney function. Exact dosing and timing should be confirmed in the current prescribing information on DailyMed.

Missed or Delayed Doses

Hospital staff manage missed or delayed doses. Patients should not try to make up doses on their own.

Kidney Function and Dose Adjustment

Why Kidney Function Matters

Cefiderocol is cleared by the kidneys, so reduced kidney function can increase drug exposure. The label includes dose adjustments based on creatinine clearance, and kidney function is monitored during therapy because it can change quickly in sick patients.

Monitoring

Clinicians check creatinine before starting treatment and repeat the test during the course. Changes in urine output, hydration, or other medications can prompt adjustments.

Dialysis

Patients on dialysis need individualized dosing planned with nephrology and pharmacy teams.

Common Side Effects

Gastrointestinal Effects

Nausea, diarrhea, and vomiting can occur. Most are mild. Persistent or bloody diarrhea needs prompt evaluation because C. difficile infection can occur with nearly all antibiotics.

Laboratory Changes

Changes in liver tests, blood counts, and electrolytes have been reported with cephalosporin-class drugs. Your team may check labs during treatment.

Infusion Reactions

Pain, redness, or swelling at the IV site can happen. Report these to your nurse so the line can be checked.

Other Effects

Headache, rash, and fever have been reported in clinical use. Report any new rash, especially one with blistering or mouth sores.

Serious Risks and Warnings

Mortality Warning

The most important warning is the higher all-cause mortality observed in the CREDIBLE-CR trial, discussed above. This is why cefiderocol is reserved for patients with limited alternatives.

Hypersensitivity Reactions

Serious allergic reactions, including anaphylaxis, can occur with beta-lactam antibiotics. Hives, facial swelling, trouble breathing, or fainting require emergency care.

C. difficile Infection

C. difficile can cause severe diarrhea and colitis. Any new or worsening diarrhea during or after treatment should be reported promptly.

Seizures and Neurologic Effects

Beta-lactam antibiotics can cause neurologic effects, particularly when drug levels build up in reduced kidney function. Report confusion, seizures, or unusual movements.

Resistance and Stewardship

Why Resistance Is a Concern

Resistance to cefiderocol can develop, particularly with prolonged exposure or inappropriate use. The label warns that use in the absence of a proven or strongly suspected bacterial infection may increase the risk of drug-resistant bacteria.

Culture First

Susceptibility testing before and during therapy helps ensure the drug is used only when needed and that the choice matches the organism.

Protecting the Drug

A last-line antibiotic is valuable only while it works. Hospitals review prescribing patterns to protect cefiderocol and other reserve agents.

Who Should Not Receive Fetroja

Known Allergy

People with a known allergy to cefiderocol or other cephalosporins should not receive Fetroja. Your team reviews your allergy history before treatment.

Serious Beta-Lactam Reactions

A history of severe reactions to penicillins or cephalosporins requires careful individual assessment.

Alternatives Available

Because of the mortality warning and the stewardship limits, Fetroja is generally not used when effective alternatives exist. The decision rests on culture results and clinical judgment.

Drug Interactions

Medication Review

Give your care team a full list of medications, including prescriptions, over-the-counter products, and supplements. Pharmacists check for interactions before starting any new antibiotic.

Nephrotoxic and Neurotoxic Drugs

Medicines that affect the kidneys or nervous system deserve attention because they can compound risks during treatment. Your team will review these in advance.

How Fetroja Compares With Other Options

Imipenem/Cilastatin

Imipenem/cilastatin was the comparator in APEKS-cUTI. Cefiderocol met noninferiority on the composite endpoint in that trial.

Colistin

Colistin is an older agent with significant kidney and nerve toxicity. Clinicians may consider it for some resistant infections, but cefiderocol and other newer agents have changed some decision-making.

Other Newer Agents

Several newer combinations are available for resistant gram-negative infections. Choice depends on the organism, resistance mechanism, infection site, and local patterns.

The 2020 Pneumonia Expansion

What Changed

On September 28, 2020, the FDA approved Fetroja for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, expanding the label beyond cUTI.

Why the Warning Matters Here

Hospital-acquired and ventilator-associated pneumonia are areas where the mortality concern is most relevant, because these patients are often critically ill. Clinicians weigh the warning carefully in these settings.

Availability and Cost

Availability

Fetroja is given in hospital and infusion settings. Availability depends on the facility, so your care team can confirm stock.

Cost

Fetroja is a branded specialty antibiotic and is expensive. Costs are often bundled into the hospital stay. Ask your insurer or hospital financial counselor for current figures.

Coverage

Coverage for FDA-approved indications is generally more straightforward. Prior authorization may be required, and pharmacy staff can help.

Pregnancy, Breastfeeding, and Children

Pregnancy

Pregnant patients with complicated UTIs need careful evaluation because untreated infection carries risks. Decisions about cefiderocol should involve the obstetric and infectious disease teams, weighing benefits against the limited data available.

Breastfeeding

Discuss breastfeeding with your care team before treatment so they can consider the infant's needs.

Children

The cUTI label is for adults aged 18 and older. Use in children is outside the labeled indication and requires specialist judgment.

Questions to Ask Your Care Team

• Did my culture identify an organism susceptible to cefiderocol, and what other options exist?
• Given the mortality warning, why is this drug the best choice for my infection?
• How will my kidney function be monitored, and how will my dose be adjusted?
• What signs of confusion, seizure, or severe diarrhea should the nurses report right away?
• Are any of my current medications a concern with this drug?

Frequently Asked Questions

Q: What is Fetroja used for?

A: Fetroja is approved for adults with complicated urinary tract infections, including pyelonephritis, caused by susceptible gram-negative organisms when few or no alternatives exist. Since 2020, it is also approved for hospital-acquired and ventilator-associated bacterial pneumonia.

Q: When was it approved?

A: The FDA approved it for cUTI on November 14, 2019.

Q: Is Fetroja a pill?

A: No. It is given only by IV infusion.

Q: What is the mortality warning?

A: In the CREDIBLE-CR trial, more patients died in the cefiderocol group than in the comparison group. The FDA said the cause was not established, and the drug is reserved for patients with limited alternatives.

Q: How does cefiderocol get into bacteria?

A: It binds iron, and bacteria actively transport iron into their cells. Cefiderocol uses this route to enter gram-negative organisms.

Q: Is it safe for kidney disease?

A: It can be used with dose adjustment based on kidney function. Your care team monitors kidney function closely during treatment.

Q: What if I have diarrhea during treatment?

A: Tell your team promptly. Persistent or bloody diarrhea needs evaluation, including testing for C. difficile.

Medical Disclaimer

This article is for general education only and does not provide medical advice, diagnosis, or treatment. Complicated urinary tract infections and pneumonia can be serious and require evaluation by a qualified clinician. Do not start, stop, or change any antibiotic without guidance from your care team. For dosing, warnings, and interactions, consult the current U.S. prescribing information on DailyMed. If you have fever with chills, flank pain, confusion, seizures, or difficulty breathing, seek emergency care immediately.

Sources and Further Reading

• U.S. FDA announcement: FDA approves new antibacterial drug to treat complicated urinary tract infections, November 14, 2019
• U.S. FDA Benefit-Risk Considerations for Cefiderocol (Fetroja), Clinical Infectious Diseases review
• Drugs.com Fetroja FDA approval history, including the September 28, 2020 HABP/VABP approval
• Healio and Medscape coverage of the FDA approval and Antimicrobial Drugs Advisory Committee vote
• APEKS-cUTI and CREDIBLE-CR trial summaries (ClinicalTrials.gov NCT02714595 and NCT02321800)
• Fetroja U.S. Prescribing Information, including the boxed warning and dosing for renal function

This article reflects information available as of October 2026. Confirm current prescribing details with your healthcare provider and the latest FDA labeling. For more on antibiotic options, visit MyOnlineMedShop blog or contact us.